This is a low-concern Form 144. Director Bjork appears to be executing a cashless exercise/sale, likely to cover option exercise costs and tax obligations. No earnings catalyst or lock-up expiry coincides. The sale volume is immaterial (~0.5% of average daily volume estimate) and should not be read as a bearish signal. Monitor for Form 4 filings to confirm whether the sale actually executed.
PHVS drugs
PHVS drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 21 $30.54entry
- T+1 · 6mo ago −2.82%α −3.26% · $29.68
- T+5 · 6mo ago −1.24%α −3.09% · $30.16
- T+20 · 5mo ago +8.07%α +7.74% · $33.01
- T+60 · 3mo ago +15.65%α +11.35% · $35.32
Price Chart
How similar events traded
Executive Summary
Form 144: Director Elisabeth Bjork intends to sell 10,000 PHVS shares (~$293K) via a cashless stock option exercise. The sale is modest relative to the company's $2.0B market cap (0.015% dilution). While the insider is a director, the amount is small and routine, this is a low-significance notification of a planned sale, not a distressed liquidation.
Key Facts
- Insider Elisabeth Bjork (Director) proposes to sell 10,000 PHVS shares
- Estimated aggregate market value: $293,166 based on ~$29.32/share implied
- Shares acquired via stock option exercise (cashless) on 5/20/2026
- Sale is being conducted through Morgan Stanley Smith Barney
- The proposed sale represents ~0.015% of the $2.0B market cap
Financial Impact
~$293K in insider selling, negligible relative to $2.0B market cap
Risk Factors
- Form 144 is an intent notification, not a completed sale, the trade may not execute
- Director selling at current levels may signal limited near-term upside conviction
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-004861 |
| Document: 0001950047-26-004861-index.html | 0001950047-26-004861 |
| Document: 0001950047-26-004861.txt | 0001950047-26-004861 |
Track record
51 reports on PHVS
15 of 18 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 17 of 19 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
- Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Nov 12, 20264d ago 6-K Neutral 4/10 No price data
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
- Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers